Dupilumab Should Be Considered As Treatment Option For Bullous Pemphigoid As dupilumab, a recombinant fully human igg4 monoclonal antibody with binding specificity to human interleukin 4 receptor il 4rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with bp. Ly elderly patient population because they work by suppressing their immune system. by targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, dupixent is the first investigational biologic to show sustained disease remiss.
Dupixent Achieves Breakthrough In Bullous Pemphigoid Treatment Market We report a case of a patient with recalcitrant bullous pemphigoid effectively treated with dupilumab. keywords: bullous pemphigoid, dupilumab, biologics, bullous disease. bullous pemphigoid (bp) occurs most commonly in patients over age 50 and is an autoimmune bullous skin disease. Question what is the efficacy and safety of dupilumab in treating patients with bullous pemphigoid? findings in this retrospective cohort study of 146 patients with bullous pemphigoid, 127 (87%) achieved disease control within 4 weeks, and the safety profile was favorable. patients with serum anti bp180 antibody levels of at least 50 relative. This retrospective study from 3 academic institutions evaluates the outcomes of 17 patients diagnosed with bp, with reported biopsy with hematoxylin and eosin stain, biopsy with direct immunofluorescence, and or serology [bullous pemphigoid antigen 1 (bp230) and bullous pemphigoid antigen 2 (bp180)], on dupilumab for at least 6 months. A dupixent (dupilumab) pivotal study (adept) in bullous pemphigoid (bp) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate to severe disease. in the study, five times more dupixent patients achieved sustained disease remission compared to those on placebo.
Can Dupixent Plug Treatment Gap In Bullous Pemphigoid Pharmaphorum This retrospective study from 3 academic institutions evaluates the outcomes of 17 patients diagnosed with bp, with reported biopsy with hematoxylin and eosin stain, biopsy with direct immunofluorescence, and or serology [bullous pemphigoid antigen 1 (bp230) and bullous pemphigoid antigen 2 (bp180)], on dupilumab for at least 6 months. A dupixent (dupilumab) pivotal study (adept) in bullous pemphigoid (bp) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate to severe disease. in the study, five times more dupixent patients achieved sustained disease remission compared to those on placebo. Il 4 and il 13 inhibitor dupixent (dupilumab) has started a priority review at the fda and is the first biologic drug to show an improvement in remission and symptoms in bp, and the first to. A potential new treatment for bullous pemphigoid (bp) is on the horizon as the u.s. food and drug administration (fda) grants priority review to dupixent’s (dupilumab) supplemental biologics license application (sbla). Positive results from the adept phase ii iii study indicate that dupixent (dupilumab) may be effective in treating moderate to severe bullous pemphigoid (bp). the findings were presented at the 2025 american academy of dermatology annual meeting. bp is a chronic skin disease characterized by intense itching, blisters, and painful lesions. Regeneron and sanofi announced that the fda accepted for priority review their supplemental biologics license application for dupixent (dupilumab) to treat bullous pemphigoid (bp) in adults. the application is supported by positive pivotal trial data showing significantly improved sustained disease remission rates with dupixent compared to placebo.
Bullous Pemphigoid Treatments Medint Il 4 and il 13 inhibitor dupixent (dupilumab) has started a priority review at the fda and is the first biologic drug to show an improvement in remission and symptoms in bp, and the first to. A potential new treatment for bullous pemphigoid (bp) is on the horizon as the u.s. food and drug administration (fda) grants priority review to dupixent’s (dupilumab) supplemental biologics license application (sbla). Positive results from the adept phase ii iii study indicate that dupixent (dupilumab) may be effective in treating moderate to severe bullous pemphigoid (bp). the findings were presented at the 2025 american academy of dermatology annual meeting. bp is a chronic skin disease characterized by intense itching, blisters, and painful lesions. Regeneron and sanofi announced that the fda accepted for priority review their supplemental biologics license application for dupixent (dupilumab) to treat bullous pemphigoid (bp) in adults. the application is supported by positive pivotal trial data showing significantly improved sustained disease remission rates with dupixent compared to placebo.
Comments are closed.